Share this article
Share this article
RADNOR, Pa. and GENEVA, Switzerland, Dec. 30, 2020 /PRNewswire/ NeuroRx, Inc. and RELIEF THERAPEUTICS Holding AG (SIX: RLF,OTCQB: RLFTF) ( Relief ) today announced the conclusion of enrollment in the phase 2b/3 trial of ZYESAMI™ (previously RLF-100
TM: aviptadil) for the treatment of Respiratory Failure in patients with Critical COVID-19 (www.clinicaltrials.gov NCT04311697). No drug-related serious adverse events have been reported as of today. Enrollment was increased from 165 patients in order to amass as large a safety database as possible. Top line data are expected in late January - early February 2021. With FDA s authorization and the extraordinary dedication of our twelve clinical trial sites, we were able to take a drug not formulated or administered to patients in IV form since 2005 and advance it to the clinic in ten weeks. We hope that the highly encouraging results seen in the most critically-ill COVID-19 patients treat
Geneva
Gene
Switzerland
United-states
Swiss
Eli-lilly
Anne-hennecke-brittney-sojeva
Jonathanc-javitt
David-schull
Raghuram-ram-selvaraju
Robert-besthof
Jonathan-javitt
TMCnet News
Chi-Med Initiates Rolling Submission of NDA to U.S. FDA for Surufatinib for the Treatment of Advanced Neuroendocrine Tumors
[December 28, 2020]
Chi-Med Initiates Rolling Submission of NDA to U.S. FDA for Surufatinib for the Treatment of Advanced Neuroendocrine Tumors
â Company plans to complete rolling submission in the first half of 2021 â
â The pivotal Phase III SANET-ep trial demonstrated surufatinib reduced risk of progression or death by 67%, extending PFS of
non-pancreatic NET patients with an acceptable risk/benefit ratio â
â The pivotal Phase III SANET-p trial demonstrated surufatinib reduced risk of progression or death by 51%, extending PFS of
pancreatic NET patients with an acceptable risk/benefit ratio â
China
Japan
Shanghai
Mark-lee
Zhou-yi
Freddy-crossley-atholl-tweedie
Marek-kania
Ben-atwell-alex-shaw
Annie-cheng
Hutchison-china-meditech-limited-chi
Drug-administration
Surufatinib-development